JP2010539981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539981A5 JP2010539981A5 JP2010528054A JP2010528054A JP2010539981A5 JP 2010539981 A5 JP2010539981 A5 JP 2010539981A5 JP 2010528054 A JP2010528054 A JP 2010528054A JP 2010528054 A JP2010528054 A JP 2010528054A JP 2010539981 A5 JP2010539981 A5 JP 2010539981A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable region
- seq
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 25
- 102000003735 Mesothelin Human genes 0.000 claims description 18
- 108090000015 Mesothelin Proteins 0.000 claims description 18
- 206010033128 Ovarian cancer Diseases 0.000 claims description 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 206010027406 Mesothelioma Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 101710112752 Cytotoxin Proteins 0.000 claims description 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
- 239000002619 cytotoxin Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 6
- 230000002357 endometrial effect Effects 0.000 claims description 6
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 6
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims description 5
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 5
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims description 5
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims description 5
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims description 5
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000030427 mucinous ovarian cancer Diseases 0.000 claims description 5
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims description 5
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 101150000931 L6 gene Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 3
- 108010008629 CA-125 Antigen Proteins 0.000 claims description 2
- 102000007269 CA-125 Antigen Human genes 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000004712 monophosphates Chemical class 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 13
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 8
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 8
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97662607P | 2007-10-01 | 2007-10-01 | |
| US60/976,626 | 2007-10-01 | ||
| US99169207P | 2007-11-30 | 2007-11-30 | |
| US60/991,692 | 2007-11-30 | ||
| US7739708P | 2008-07-01 | 2008-07-01 | |
| US61/077,397 | 2008-07-01 | ||
| PCT/US2008/078123 WO2009045957A1 (en) | 2007-10-01 | 2008-09-29 | Human antibodies that bind mesothelin, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539981A JP2010539981A (ja) | 2010-12-24 |
| JP2010539981A5 true JP2010539981A5 (enExample) | 2011-08-25 |
| JP5535074B2 JP5535074B2 (ja) | 2014-07-02 |
Family
ID=40526631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528054A Expired - Fee Related JP5535074B2 (ja) | 2007-10-01 | 2008-09-29 | メソテリンに結合するヒト抗体およびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US8268970B2 (enExample) |
| EP (1) | EP2195017B1 (enExample) |
| JP (1) | JP5535074B2 (enExample) |
| KR (2) | KR101554848B1 (enExample) |
| CN (1) | CN101951946B (enExample) |
| AR (1) | AR068590A1 (enExample) |
| AU (1) | AU2008308956B2 (enExample) |
| BR (1) | BRPI0816014A8 (enExample) |
| CA (1) | CA2700860C (enExample) |
| CL (1) | CL2008002923A1 (enExample) |
| CO (1) | CO6300960A2 (enExample) |
| CY (1) | CY1116036T1 (enExample) |
| DK (1) | DK2195017T3 (enExample) |
| EA (1) | EA018396B1 (enExample) |
| ES (1) | ES2526355T3 (enExample) |
| HR (1) | HRP20150074T1 (enExample) |
| IL (2) | IL204615A (enExample) |
| MX (1) | MX2010003581A (enExample) |
| NZ (1) | NZ584633A (enExample) |
| PL (1) | PL2195017T3 (enExample) |
| PT (1) | PT2195017E (enExample) |
| RS (1) | RS53760B1 (enExample) |
| SI (1) | SI2195017T1 (enExample) |
| TW (1) | TWI446922B (enExample) |
| WO (1) | WO2009045957A1 (enExample) |
| ZA (1) | ZA201002313B (enExample) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| HRP20150074T1 (hr) * | 2007-10-01 | 2015-03-13 | Bristol-Myers Squibb Company | Humana antitijela koja se vežu za mezotelin i njihove uporabe |
| MX2010005603A (es) * | 2007-11-26 | 2010-08-02 | Bayer Schering Pharma Ag | Anticuerpos antimesotelina y usos de los mismos. |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| EP3296321B1 (en) * | 2010-12-20 | 2020-07-15 | F. Hoffmann-La Roche AG | Anti-mesothelin antibodies and immunoconjugates |
| RU2610336C2 (ru) | 2011-04-21 | 2017-02-09 | Сиэтл Дженетикс, Инк. | Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| SG11201404667XA (en) | 2012-02-13 | 2014-09-26 | Bristol Myers Squibb Co | Enediyne compounds, conjugates thereof, and uses and methods therefor |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| AU2013306076B2 (en) * | 2012-08-21 | 2018-01-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| EP2900695B1 (en) * | 2012-09-27 | 2018-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| LT2956173T (lt) | 2013-02-14 | 2017-06-26 | Bristol-Myers Squibb Company | Tubulizino junginiai, gavimo ir panaudojimo būdai |
| JP6574754B2 (ja) | 2013-03-19 | 2019-09-11 | ベイジン シェノゲン ファーマ グループ リミテッド | エストロゲン受容体関連疾患を処置するための抗体及び方法 |
| CA2921401A1 (en) | 2013-08-14 | 2015-02-19 | William Marsh Rice University | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| EP4026909A1 (en) | 2013-12-19 | 2022-07-13 | Novartis AG | Human mesothelin chimeric antigen receptors and uses thereof |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| JP2017518053A (ja) * | 2014-06-06 | 2017-07-06 | メモリアル スローン−ケタリング キャンサー センター | メソセリン標的化キメラ抗原受容体およびその使用 |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| LT3221363T (lt) | 2014-11-21 | 2020-08-10 | Bristol-Myers Squibb Company | Antikūnai prieš cd73 ir jų panaudojimas |
| EP3789399A1 (en) | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
| CN107428780B (zh) | 2015-01-14 | 2020-09-04 | 百时美施贵宝公司 | 苯并二氮杂*二聚体、其缀合物及制备和使用方法 |
| AU2016206808A1 (en) | 2015-01-14 | 2017-08-31 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US10676773B2 (en) | 2015-03-10 | 2020-06-09 | Bristol-Myers Squibb Company | Antibodies conjugatable by transglutaminase and conjugates made therefrom |
| KR102740444B1 (ko) | 2015-04-17 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| CA2996060A1 (en) * | 2015-08-21 | 2017-03-02 | Carsgen Therapeutics, Ltd | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| ES2926969T3 (es) | 2015-11-19 | 2022-10-31 | Bristol Myers Squibb Co | Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos |
| WO2017112624A1 (en) | 2015-12-21 | 2017-06-29 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| KR20230038311A (ko) | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| PL3443096T3 (pl) | 2016-04-15 | 2023-06-19 | Novartis Ag | Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych |
| CA3019841A1 (en) * | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| JP2019518013A (ja) | 2016-05-10 | 2019-06-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 安定性が向上したツブリシン類似体の抗体薬物結合体 |
| CN115350263A (zh) | 2016-05-20 | 2022-11-18 | 拜尔哈文制药股份有限公司 | 谷氨酸调节剂与免疫疗法用以治疗癌症的用途 |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| JP2019527696A (ja) | 2016-08-01 | 2019-10-03 | ノバルティス アーゲー | プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置 |
| WO2018035391A1 (en) | 2016-08-19 | 2018-02-22 | Bristol-Myers Squibb Company | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use |
| WO2018048975A1 (en) * | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| EP3541423A4 (en) * | 2016-11-18 | 2020-10-07 | The Regents of The University of California | MODIFIED ANTIBODIES AND THEIR USES |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| US11384098B2 (en) | 2017-02-08 | 2022-07-12 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US11142570B2 (en) | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US11685787B2 (en) | 2017-05-16 | 2023-06-27 | Bristol-Myers Squibb Company | Treatment of cancer with anti-GITR agonist antibodies |
| KR20240149979A (ko) | 2017-05-25 | 2024-10-15 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| KR101966362B1 (ko) * | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| CA3087058A1 (en) * | 2017-12-26 | 2019-07-04 | The Regents Of The University Of California | Human antibodies that bind and are internalized by mesothelioma and other cancer cells |
| KR102761890B1 (ko) | 2018-03-23 | 2025-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | Mica 및/또는 micb에 대한 항체 및 그의 용도 |
| JP2021519771A (ja) | 2018-03-30 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍を処置する方法 |
| JP2021521182A (ja) | 2018-04-12 | 2021-08-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療 |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| BR112020024022A2 (pt) | 2018-05-29 | 2021-02-23 | Bristol-Myers Squibb Company | porções autoimolantes modificadas para uso em profármacos e conjugados e métodos de uso e preparação |
| EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| JP2021527706A (ja) * | 2018-06-18 | 2021-10-14 | アンウィタ バイオサイエンシス， インク． | 抗メソテリンコンストラクト及びその使用 |
| US11020490B2 (en) | 2018-06-22 | 2021-06-01 | Bristol-Myers Squibb Company | Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN110746508B (zh) * | 2018-07-23 | 2023-04-14 | 上海细胞治疗集团有限公司 | 特异性结合间皮素的单克隆抗体及嵌合抗原受体 |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| CN113348177A (zh) | 2018-11-28 | 2021-09-03 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
| CN113453725A (zh) | 2018-11-30 | 2021-09-28 | 百时美施贵宝公司 | 包含含有谷氨酰胺的轻链c末端延伸的抗体、其缀合物以及方法和用途 |
| CN113544155A (zh) | 2018-12-12 | 2021-10-22 | 百时美施贵宝公司 | 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途 |
| US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN109705219B (zh) * | 2019-01-08 | 2020-11-13 | 上海霖科生物科技有限公司 | 与间皮素结合的单克隆抗体及其制备方法 |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CN110698562B (zh) * | 2019-10-31 | 2022-10-25 | 浙江蓝盾药业有限公司 | 抗人msln单克隆抗体 |
| WO2021113290A1 (en) | 2019-12-03 | 2021-06-10 | Alamar Biosciences, Inc. | Nucleic acid linked immune-sandwich assay (nulisa) |
| KR20220116522A (ko) | 2019-12-20 | 2022-08-23 | 노파르티스 아게 | 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도 |
| CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| CN113698492B (zh) * | 2020-05-22 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| EP4294442A4 (en) * | 2021-02-16 | 2025-07-09 | Univ Pittsburgh Commonwealth Sys Higher Education | MESOTHELIN POLYPEPTIDE-BINDING MOLECULES |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| KR102860436B1 (ko) * | 2021-06-30 | 2025-09-19 | (주)이노베이션바이오 | 메소텔린 특이적 항체 및 이의 용도 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| MX2024007054A (es) * | 2021-12-10 | 2024-09-04 | Merck Sharp & Dohme Llc | Aglutinantes de mesotelina humana. |
| CN114423789B (zh) * | 2021-12-24 | 2022-09-30 | 浙江时迈药业有限公司 | 针对间皮素的抗体及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| US20250332252A1 (en) | 2022-06-02 | 2025-10-30 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| US20250282786A1 (en) | 2024-03-05 | 2025-09-11 | Bristol-Myers Squibb Company | Tricyclic TLR7 Agonists and Uses Thereof |
| US20250282776A1 (en) | 2024-03-05 | 2025-09-11 | Bristol-Myers Squibb Company | Bicyclic TLR7 Agonists and Uses Thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4912227A (en) | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
| US4978757A (en) | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
| US5332837A (en) | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
| US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| AU648313B2 (en) | 1990-04-25 | 1994-04-21 | Pharmacia & Upjohn Company | Novel CC-1065 analogs |
| JP2660241B2 (ja) | 1990-10-12 | 1997-10-08 | アメリカ合衆国 | モノクロナール抗体 |
| JPH0597853A (ja) | 1991-10-07 | 1993-04-20 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−８９誘導体の臭化水素酸塩 |
| JP3328341B2 (ja) | 1991-12-27 | 2002-09-24 | 中外製薬株式会社 | 新規な巨核球増幅因子 |
| IL107366A (en) | 1992-10-23 | 2003-03-12 | Chugai Pharmaceutical Co Ltd | Genes coding for megakaryocyte potentiator |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| PT705833E (pt) | 1994-04-22 | 2004-11-30 | Kyowa Hakko Kogyo Kk | Derivado de dc-89 |
| JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| AU3532895A (en) | 1994-09-30 | 1996-04-26 | Kyowa Hakko Kogyo Co. Ltd. | Antitumor agent |
| AU718138B2 (en) * | 1995-08-29 | 2000-04-06 | Kyowa Hakko Kirin Co., Ltd. | Chimeric animal and method for constructing the same |
| CA2241604C (en) | 1996-01-05 | 2010-03-30 | Ira Pastan | Mesothelium antigen and methods and kits for targeting it |
| US7375183B1 (en) | 1996-01-05 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof |
| US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| EP1025230B1 (en) | 1997-12-01 | 2006-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
| JP4813661B2 (ja) | 1999-02-26 | 2011-11-09 | パシフィック ノースウエスト リサーチ インスティテュート | 癌を診断するための方法および組成物 |
| US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| US7081518B1 (en) | 1999-05-27 | 2006-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mesothelin antibodies having high binding affinity |
| US7288390B2 (en) * | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| WO2002096910A1 (en) | 2001-05-31 | 2002-12-05 | Medarex, Inc. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| US7125663B2 (en) | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
| WO2002102235A2 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| ES2326964T3 (es) * | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| JP5425365B2 (ja) | 2003-01-22 | 2014-02-26 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 増加したＦｃレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用 |
| ES2349777T3 (es) * | 2003-01-22 | 2011-01-11 | Glycart Biotechnology Ag | Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de fc y función efectora. |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| EP1651675A1 (en) | 2003-08-05 | 2006-05-03 | Morphotek, Inc. | A variant cell surface molecule associated with cancer |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| DK1691837T3 (da) * | 2003-12-10 | 2012-10-01 | Medarex Inc | IP-10-antistoffer og anvendelse heraf |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| WO2005112919A2 (en) * | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| AU2006223301B2 (en) * | 2005-03-10 | 2010-11-04 | Eisai, Inc. | Anti-mesothelin antibodies |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| WO2006124641A2 (en) * | 2005-05-12 | 2006-11-23 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Anti-mesothelin antibodies useful for immunological assays |
| NZ566982A (en) | 2005-09-26 | 2011-06-30 | Medarex Inc | Duocarmycin drug conjugates |
| ATE534629T1 (de) | 2005-10-26 | 2011-12-15 | Medarex Inc | Verfahren und verbindungen zur herstellung von cc-1065-analoga |
| WO2007100385A2 (en) | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| MX2008009956A (es) | 2006-02-02 | 2008-12-12 | Syntarga Bv | Analogos de cc-1065 solubles en agua y sus conjugados. |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| CN101012280A (zh) * | 2007-02-07 | 2007-08-08 | 吴小华 | 抗人可溶性间皮素相关蛋白单克隆抗体的制备方法 |
| AR065404A1 (es) | 2007-02-21 | 2009-06-03 | Medarex Inc | Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero |
| HRP20150074T1 (hr) * | 2007-10-01 | 2015-03-13 | Bristol-Myers Squibb Company | Humana antitijela koja se vežu za mezotelin i njihove uporabe |
| MX2010005603A (es) * | 2007-11-26 | 2010-08-02 | Bayer Schering Pharma Ag | Anticuerpos antimesotelina y usos de los mismos. |
-
2008
- 2008-09-29 HR HRP20150074AT patent/HRP20150074T1/hr unknown
- 2008-09-29 EP EP08836490.6A patent/EP2195017B1/en active Active
- 2008-09-29 WO PCT/US2008/078123 patent/WO2009045957A1/en not_active Ceased
- 2008-09-29 CN CN200880110024.5A patent/CN101951946B/zh not_active Expired - Fee Related
- 2008-09-29 DK DK08836490.6T patent/DK2195017T3/en active
- 2008-09-29 ES ES08836490.6T patent/ES2526355T3/es active Active
- 2008-09-29 PL PL08836490T patent/PL2195017T3/pl unknown
- 2008-09-29 CA CA2700860A patent/CA2700860C/en not_active Expired - Fee Related
- 2008-09-29 AU AU2008308956A patent/AU2008308956B2/en not_active Ceased
- 2008-09-29 RS RS20150044A patent/RS53760B1/sr unknown
- 2008-09-29 MX MX2010003581A patent/MX2010003581A/es active IP Right Grant
- 2008-09-29 KR KR1020157008793A patent/KR101554848B1/ko not_active Expired - Fee Related
- 2008-09-29 BR BRPI0816014A patent/BRPI0816014A8/pt not_active Application Discontinuation
- 2008-09-29 SI SI200831341T patent/SI2195017T1/sl unknown
- 2008-09-29 US US12/681,215 patent/US8268970B2/en active Active
- 2008-09-29 NZ NZ584633A patent/NZ584633A/en not_active IP Right Cessation
- 2008-09-29 JP JP2010528054A patent/JP5535074B2/ja not_active Expired - Fee Related
- 2008-09-29 KR KR1020107009426A patent/KR101554753B1/ko not_active Expired - Fee Related
- 2008-09-29 EA EA201070412A patent/EA018396B1/ru not_active IP Right Cessation
- 2008-09-29 PT PT88364906T patent/PT2195017E/pt unknown
- 2008-09-30 CL CL2008002923A patent/CL2008002923A1/es unknown
- 2008-09-30 AR ARP080104267A patent/AR068590A1/es unknown
- 2008-10-01 TW TW097137770A patent/TWI446922B/zh not_active IP Right Cessation
-
2010
- 2010-03-18 IL IL204615A patent/IL204615A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02313A patent/ZA201002313B/en unknown
- 2010-04-27 CO CO10049719A patent/CO6300960A2/es active IP Right Grant
-
2012
- 2012-08-16 US US13/587,572 patent/US8383779B2/en active Active
- 2012-08-16 US US13/587,500 patent/US8399623B2/en active Active
- 2012-08-16 US US13/587,644 patent/US8425904B2/en active Active
-
2013
- 2013-03-14 US US13/827,946 patent/US20130190481A1/en not_active Abandoned
-
2015
- 2015-01-21 CY CY20151100062T patent/CY1116036T1/el unknown
- 2015-12-28 IL IL243375A patent/IL243375B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539981A5 (enExample) | ||
| AU2019320336B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| JP7769032B2 (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| TW201920078A (zh) | 抗體－藥物結合物之新穎製造方法 | |
| BR112021011014A2 (pt) | Anticorpos anti-claudina e usos destes | |
| CN113271942A (zh) | 抗体-药物缀合物与parp抑制剂的组合 | |
| JP2017186337A5 (enExample) | ||
| JPWO2018066626A1 (ja) | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 | |
| BRPI0620632A2 (pt) | composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição farmacêuticas, e kits | |
| JPWO2021177438A5 (enExample) | ||
| EP3804764A1 (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate | |
| WO2021252578A1 (en) | Anti-human neurotensin receptor 1 antibody and use thereof | |
| EP2710038B1 (en) | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER | |
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| BR122024023393A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| BR122024023391A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| WO2024248123A1 (ja) | 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ | |
| CA3101906C (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate | |
| WO2024210162A1 (ja) | 抗ｍｕｃ１抗体－薬物コンジュゲート投与による薬剤低感受性がんの治療方法 | |
| TW202542159A (zh) | 新抗體藥物結合物以及其製造方法及用途 | |
| HK40043732A (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| WO2025120090A1 (en) | Antibody-drug conjugate comprising an anti-gucy2c antibody as well as methods of production and uses thereof | |
| EA050611B1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина | |
| BR122023026672A2 (pt) | Uso de um conjugado de anticorpo-fármaco | |
| BR122023026675A2 (pt) | Uso de um conjugado de anticorpo-fármaco |